Congrats Dexcom

Congrats Dexcom

Late yesterday Dexcom (NASDAQ: DXCM) received word that the Centers for Medicare & Medicaid Services (CMS) will classify Therapeutic Continuous Glucose Monitors (CGM) as “Durable Medical Equipment” under Medicare Part B. Per a company issued press release;

“DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, is pleased to announce the determination of a benefit category and coverage for CGM by CMS. In order to be included in this category, the system must be defined as “therapeutic” CGM, meaning you can make treatment decisions using the device. Today, the Dexcom G5 Mobile is the only CGM system that falls within this classification.”

While Diabetic Investor is not surprised by this decision it does pave the way for market expansion on multiple levels as private payers model their coverage decisions on what CMS does. Perhaps this decision, a very nice step forward, will stop analysts from going off the reservation anytime Dexcom hits the occasional bump in the road.

Diabetic Investor has said it many times but here it is well worth repeating, when it comes to this wacky world of diabetes talent, true talent is in short supply. And talent is something Dexcom has in abundance and as Momma Kliff used to say; “Talent is like money and good health you can never have too much of it.”

So, kudos to all the good people at Dexcom take a bow for a job very well played. The folks at Dexcom continue to demonstrate why they are the standard for how a diabetes should be run. Fundamentally the folks at Dexcom get it as they know when you put the interest of the patient first everything else falls into place.